C. difficile

The agency cleared the automated qualitative IVD test last month for the detection of the toxin B gene of toxigenic Clostridium difficile.

The firm said that it is delaying clinical trials prior to its FDA submission of Verigene 2 for several reasons, including reducing cassette failure rates.

The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent. 

The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.

PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.

The test can generate results in around 35 minutes from stool samples and requires no upfront nucleic acid extraction.

Analyses of Clostridium difficile isolates from hundreds of European hospitals led to clusters of apparent hospital-acquired cases and of infections with other potential sources.

Just Pop On In

The stool bank OpenBiome has a new storefront in Massachusetts, WGBH News reports.

The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.

The assay has been available outside the US since November and runs on the Liaison MDX benchtop instrument. 

Pages

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.